Hope, Concern Surround WHO Green Light of First Malaria Vaccine

RTS,S has several flaws but could still save tens of thousands of lives, experts say.

Written byKatarina Zimmer
| 10 min read
close-up of a mosquito on human skin

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

ABOVE: © ISTOCK.COM, MRFIZA

Plasmodium parasites are as stealthy as pathogens come. The malaria-causing single-celled organisms have been adapting to the human lineage for longer than our species has existed, giving them millions of years of training in evading our immune systems and—until recently—an unshakable advantage over vaccine developers.

While SARS-CoV-2, the virus that causes COVID-19, only has 29 proteins, Plasmodium species have thousands. SARS-CoV-2’s spike protein, which it uses to invade human cells, is an obvious bullseye for vaccines, but Plasmodium is a moving target. After mosquitoes inject Plasmodium sporozoites into the bloodstream, the parasites hide away and multiply in liver cells, from which they emerge as bloodborne merozoites, which commence fever-inducing invasions of red blood cells. Some of the parasites shapeshift yet again and are picked up through mosquito bites. For each life stage, Plasmodium transforms its cloak of proteins—a challenge to vaccinologists. Many vaccine efforts have failed ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies